A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers.
source https://www.sciencedaily.com/releases/2020/12/201209115232.htm
Thursday, 10 December 2020
Related Posts
As climate warms, summer monsoons to produce less streamflowA new study points to both the importance of monsoon rains in maintain… Read More
Biosensors require robust antifouling protectionSome promising biosensors and medical devices work well within pristin… Read More
Marine organisms use previously undiscovered receptors to detect, respond to lightSingle-celled organisms in the open ocean use a diverse array of newly… Read More
Research finds COVID plasma donation is fuelled by kindnessResearchers have given new insights into why people would choose to do… Read More
Neutrons probe molecular behavior of proposed COVID-19 drug candidatesUsing neutron experiments and computer simulations, researchers delved… Read More
Lack of ICU beds tied to thousands of excess COVID-19 deaths, study findsA new study has found a significant association between the availabili… Read More
0 comments: